Amicus Therapeutics, Inc. (FOLD) Stake Increased by Candriam Luxembourg S.C.A., Report finds

Amicus Therapeutics, Inc. (FOLD) Stake Increased by Candriam Luxembourg S.C.A., Report finds

Candriam Luxembourg S.C.A. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 39.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 986,900 shares of the biopharmaceutical company’s stock after buying an additional 277,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.69% of Amicus Therapeutics worth $7,303,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its stake in Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares in the last quarter. Endurant Capital Management LP bought a new stake in shares of Amicus Therapeutics during the third quarter worth approximately $317,000. Berson & Corrado Investment Advisors LLC boosted its stake in shares of Amicus Therapeutics by 283.9% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 42,995 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 31,795 shares during the period. Numeric Investors LLC bought a new stake in shares of Amicus Therapeutics during the second quarter worth approximately $414,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Amicus Therapeutics by 14.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 92,989 shares of the biopharmaceutical company’s stock worth $508,000 after buying an additional 11,881 shares during the period.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded up 1.50% on Wednesday, hitting $6.11. The company had a trading volume of 3,812,047 shares. The company has a 50 day moving average of $5.40 and a 200-day moving average of $6.70. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $9.83. The company’s market cap is $869.61 million.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.01. The firm had revenue of $2.10 million for the quarter, compared to analyst estimates of $1.71 million. On average, analysts forecast that Amicus Therapeutics, Inc. will post ($1.40) earnings per share for the current year.

A number of equities research analysts have commented on the company. Robert W. Baird upgraded Amicus Therapeutics to an “outperform” rating in a report on Tuesday, January 31st. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 9th. Cowen and Company set a $12.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, December 8th. Leerink Swann reiterated an “outperform” rating and set a $15.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, November 30th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $11.00 target price (down previously from $12.00) on shares of Amicus Therapeutics in a report on Wednesday, November 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $11.42.

In other news, major shareholder Perceptive Advisors Llc purchased 85,275 shares of the stock in a transaction that occurred on Friday, December 23rd. The shares were purchased at an average cost of $4.81 per share, for a total transaction of $410,172.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Hung Do sold 25,000 shares of the business’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $6.00, for a total value of $150,000.00. Following the transaction, the insider now owns 559,266 shares in the company, valued at $3,355,596. The disclosure for this sale can be found here. In the last three months, insiders have acquired 511,650 shares of company stock valued at $2,426,927. Company insiders own 3.40% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Related posts

Leave a Comment

Amicus Therapeutics, Inc. (FOLD) Stake Increased by Candriam Luxembourg S.C.A.

Amicus Therapeutics, Inc. (FOLD) Stake Increased by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 39.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 986,900 shares of the biopharmaceutical company’s stock after buying an additional 277,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.69% of Amicus Therapeutics worth $7,303,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its stake in Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares in the last quarter. Endurant Capital Management LP bought a new stake in shares of Amicus Therapeutics during the third quarter worth approximately $317,000. Berson & Corrado Investment Advisors LLC boosted its stake in shares of Amicus Therapeutics by 283.9% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 42,995 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 31,795 shares during the period. Numeric Investors LLC bought a new stake in shares of Amicus Therapeutics during the second quarter worth approximately $414,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Amicus Therapeutics by 14.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 92,989 shares of the biopharmaceutical company’s stock worth $508,000 after buying an additional 11,881 shares during the period.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded up 1.50% on Wednesday, hitting $6.11. The company had a trading volume of 3,812,047 shares. The company has a 50 day moving average of $5.40 and a 200-day moving average of $6.70. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $9.83. The company’s market cap is $869.61 million.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.01. The firm had revenue of $2.10 million for the quarter, compared to analyst estimates of $1.71 million. On average, analysts forecast that Amicus Therapeutics, Inc. will post ($1.40) earnings per share for the current year.

A number of equities research analysts have commented on the company. Robert W. Baird upgraded Amicus Therapeutics to an “outperform” rating in a report on Tuesday, January 31st. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 9th. Cowen and Company set a $12.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, December 8th. Leerink Swann reiterated an “outperform” rating and set a $15.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, November 30th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $11.00 target price (down previously from $12.00) on shares of Amicus Therapeutics in a report on Wednesday, November 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $11.42.

In other news, major shareholder Perceptive Advisors Llc purchased 85,275 shares of the stock in a transaction that occurred on Friday, December 23rd. The shares were purchased at an average cost of $4.81 per share, for a total transaction of $410,172.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Hung Do sold 25,000 shares of the business’s stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $6.00, for a total value of $150,000.00. Following the transaction, the insider now owns 559,266 shares in the company, valued at $3,355,596. The disclosure for this sale can be found here. In the last three months, insiders have acquired 511,650 shares of company stock valued at $2,426,927. Company insiders own 3.40% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Related posts

Leave a Comment